How effective is trazodone for sleep maintenance in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Trazodone for Sleep Maintenance: Limited Efficacy

The American Academy of Sleep Medicine (AASM) explicitly recommends against using trazodone for sleep maintenance insomnia, citing insufficient evidence of efficacy. 1

Guideline Recommendations

The 2017 AASM clinical practice guideline provides a WEAK recommendation against using trazodone for both sleep onset and sleep maintenance insomnia in adults (based on 50 mg dose trials). 1 This negative recommendation stands in contrast to their positive recommendations for other agents specifically indicated for sleep maintenance, including:

  • Suvorexant (orexin receptor antagonist)
  • Eszopiclone
  • Zolpidem
  • Temazepam
  • Doxepin (3-6 mg doses)

The 2016 American College of Physicians guideline similarly concluded there was insufficient evidence to determine trazodone's effectiveness for chronic insomnia disorder. 2

FDA Labeling Context

Trazodone is FDA-approved only for major depressive disorder (MDD) in adults—not for insomnia. 3 The FDA label makes no mention of sleep maintenance as an indication, and its efficacy was established solely in depression trials. 3 Using trazodone for insomnia represents off-label prescribing without regulatory support.

Research Evidence Shows Mixed Results

Despite widespread clinical use, the evidence base is problematic:

Recent Meta-Analysis (2024)

A comprehensive systematic review found trazodone did not significantly improve subjective total sleep time (mean difference: 0.73 minutes, p=0.96). 4 However, it did show:

  • Improved sleep quality scores
  • Reduced nocturnal awakenings
  • Decreased time awake after sleep onset (13.47 minutes)
  • Increased objective total sleep time by polysomnography (27.98 minutes)

Critical caveat: These benefits came with significantly more adverse effects, including 2.3 times higher dropout rates due to side effects and 4.3 times more sleep-related adverse effects. 4

Context-Specific Efficacy

Trazodone appears more effective for sleep maintenance than sleep onset, particularly in specific populations:

  • Antidepressant-induced insomnia: Effective at 100 mg in patients on SSRIs, improving sleep continuity and deep sleep stages. 5
  • Comorbid conditions: Shows benefit in PTSD (78% reported improved sleep maintenance), 6 opioid dependence on buprenorphine (82% achieved normal sleep scores), 7 and depression with insomnia. 8
  • Timing requirement: Must be administered at least 1 hour before bedtime (unlike hypnotics), limiting its utility for sleep maintenance specifically. 9

Safety Concerns

The risk-benefit profile is concerning:

  • Priapism: One study reported 12% incidence—far higher than expected and potentially serious. 6
  • Daytime sedation: 7.34 times higher odds of somnolence versus placebo. 8
  • Blurred vision: 17.5 times higher odds. 8
  • General tolerability: More adverse effects overall (OR=1.18) and more dropouts. 4

Clinical Algorithm

For primary sleep maintenance insomnia in adults without depression:

  1. Do not use trazodone as first-line therapy per AASM guidelines 1
  2. Consider FDA-approved options: suvorexant, eszopiclone, zolpidem, or low-dose doxepin (3-6 mg)
  3. Prioritize cognitive behavioral therapy for insomnia (CBT-I) when available

For sleep maintenance insomnia with comorbid depression:

  1. Trazodone may be considered at 50-200 mg nightly 6, 5
  2. Administer at least 1 hour before bedtime 9
  3. Directly ask about priapism at follow-up visits given elevated risk 6
  4. Monitor for excessive daytime sedation and visual disturbances 8

For antidepressant-induced insomnia:

  1. Trazodone 100 mg is a reasonable option given specific evidence 5
  2. Expect improvement in sleep continuity rather than just sleep onset

Bottom Line

While trazodone is commonly prescribed off-label for sleep maintenance, major sleep medicine guidelines recommend against its use due to insufficient evidence in primary insomnia. Its efficacy appears limited to specific contexts (depression, antidepressant-induced insomnia, certain comorbidities) where the risk-benefit calculation may favor its use. For uncomplicated sleep maintenance insomnia, FDA-approved hypnotics or low-dose doxepin have stronger evidence and guideline support.

References

1
Guideline

clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2017

Related Questions

When should trazodone be taken at bedtime to aid sleep?
How can I help a 25-year-old female patient who is taking trazodone for insomnia without improvement while also on sertraline 150 mg?
Is a 1000 mg dose of trazodone a dose that requires medical observation?
Can I increase the dose of trazodone to 300 mg for insomnia?
Can trazodone hydrochloride tablets be crushed?
In a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency, is aspirin safe to use and what is the recommended maximum dose?
What questions should I ask a gastrointestinal patient presenting with dysphagia?
For a 175‑lb (≈79 kg) patient with bullous pemphigoid lesions, which oral steroid should be used and what is the appropriate dose?
What mucolytic medication is recommended for a patient with chronic obstructive pulmonary disease (COPD) and squamous cell carcinoma (SCC) of the tonsil who has a productive (wet) cough?
What should be done for a 9-year-old with suspected gastroenteritis who continues vomiting after receiving ondansetron?
How should I treat a patient with hypoalbuminemia (serum albumin <2.0 g/dL) who has edema or hypotension, including albumin infusion and management of underlying causes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.